AgingResearch.NewsJoin free

Bristol Myers

CompanyUnited States

Bristol Myers develops one asset, in phase 3 (Admilparant in idiopathic pulmonary fibrosis). Mostly small molecule acting on inflammation and LPAR1; based in the United States.

1
Asset
Furthest stage
Phase 3
0
Trials
0
Signals

Pipeline

1

  • Admilparant

    Blocks lysophosphatidic acid receptor 1 signaling to reduce fibrosis.

    Phase 3, Small molecule, Inflammation, LPAR1, idiopathic pulmonary fibrosis, progressive pulmonary fibrosis

Full company profiles: pipeline, trials, funding and people.

See Pro

In the full profile

  • Evidence behind the mechanisms3
  • Signals1
  • Integrity notices1
  • Similar companies6

Intelligence